A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-062 FOR THE TREATMENT OF ACTIVE CELIAC DISEASE IN SUBJECTS ATTEMPTING A GLUTEN-FREE DIET
- Registry ID
- TAK-062-2001
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE2
- Study type
- INTERVENTIONAL
- Sponsor
- TAKEDA DEVELOPMENT CENTER AMERICAS INC
- Start date
- 2023-05-03
- Last update
- 2022-07-29
Conditions
Related clinical trials
- A PHASE 2A/B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY
TO INVESTIGATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS AMLITELIMAB IN ADULT PATIENTS
WITH NON-RESPONSIVE CELIAC DISEASE AS AN ADJUNCT TO A GLUTEN-FREE DIET
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET
- RESTORATION OF IMPAIRED MICROBIOTA-MEDIATED ARYL HYDROCARBON RECEPTOR SIGNALING IN CELIAC DISEASE BY ORAL TRYPTOPHAN SUPPLEMENTATION: AN EXPLORATORY STUDY
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PRV-015 IN ADULT PATIENTS WITH NON-RESPONSIVE CELIAC DISEASE AS AN ADJUNCT TO A GLUTEN-FREE DIET
- A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF ALV003 TREATMENT IN SYMPTOMATIC CELIAC DISEASE PATIENTS MAINTAINED ON A GLUTEN-FREE DIET
View on source registry